According to Kangenbei's announcement, the company and its subsidiaries have added 10 new varieties, including hexamethrin and acetylcysteine, to the “National Essential Drug Catalogue”, and no drugs have been withdrawn. In addition to the additions, all the varieties that entered the 2018 edition of the company's basic drug catalogue have been retained, and a total of 76 products have been included in the catalogue. The addition and retention of products this time has a positive effect on sales of related products, which is conducive to expanding market share and enhancing competitiveness. It is expected that it will not have a significant impact on performance in the short term.

According to Kangenbei's announcement, the company and its subsidiaries have added 10 new varieties, including hexamethrin and acetylcysteine, to the “National Essential Drug Catalogue”, and no drugs have been withdrawn. In addition to the additions, all the varieties that entered the 2018 edition of the company's basic drug catalogue have been retained, and a total of 76 products have been included in the catalogue. The addition and retention of products this time has a positive effect on sales of related products, which is conducive to expanding market share and enhancing competitiveness. It is expected that it will not have a significant impact on performance in the short term.